Older adults · California
Studies for adults 50 and older in California
These studies set a minimum age of 50 or older in their official record. Many look at conditions more common with age, and some vaccine and memory studies specifically need older participants.
117 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2/Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Costa Mesa, CA + 34 other US sites
- Eligibility basics
- Ages 55–95
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Imperial, CA + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 4
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Alpha Cognition, Inc
- Location
- Irvine, CA + 21 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Anaheim, CA + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Bristol-Myers Squibb
- Location
- Anaheim, CA + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette);
Genentech, Inc.
- Location
- Beverly Hills, CA + 14 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
- Location
- Fullerton, CA + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals
- Location
- Beverly Hills, CA + 144 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
- Location
- Huntington Beach, CA + 14 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Hoffmann-La Roche
- Location
- Irvine, CA + 11 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb
- Location
- Fullerton, CA + 22 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Garden Grove, CA + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Carlsbad, CA + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Murrieta, CA + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Chino, CA + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Long Beach, CA + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Fullerton, CA + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
EyeBiotech Ltd.
- Location
- Glendale, CA + 66 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development, LLC
- Location
- Fullerton, CA + 44 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Anaheim, CA + 32 other US sites
- Eligibility basics
- Ages 55–90
- Recruiting
Post-Market Study to Assess iTind Safety in Comparison to UroLift
Olympus Corporation of the Americas
- Location
- Fresno, CA + 10 other US sites
- Eligibility basics
- Ages 50+ · Men only
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Anaheim, CA + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.
- Location
- Anaheim, CA + 22 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Irvine, CA + 27 other US sites
- Eligibility basics
- Ages 55–84